Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: ruin (2), spoil (2), blight (1)

Rituximab SC (8 weekly) Ver 1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single age
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

CHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Vincristine (21) Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-VINCRISTINE (21) (CHOP 21) Regimen Lymphoma – CHOP(21)-
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CHOP21-Cyclophosphamide-Doxorubicin-Prednisolone-Vincristine-21-Ver-1.2.pdf

Southampton PTC - Approved chemotherapy regimens 9 June 2020

Description: Appendix B: SOUTHAMPTON PAEDIATRIC ONCOLOGY PRINCIPAL TREATMENT CENTRE List of Approved Chemotherapy Regimens Updated 9th June
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/Southampton-PTC-Approved-chemotherapy-regimens-9-June-2020.pdf

InP RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Ver1.1

Description: Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVE) Inpatient Regimen Regimen Lymphoma – InP-RIVE-Epirub
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab.pdf

BEACON protocol v8.0 07Mar2023 signed

Description: A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory/relapsed eu
Url: /Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

NIHR BioBank participant info sheet_v4

Description: PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-BioBank-participant-info-sheet-v4.pdf

NIHR_RTB_PIS-ICF_v4.1_15Mar2023Localised

Description: PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v4.1-15Mar2023Localised.pdf

NIHR_RTB_PIS-ICF_v4.1_15Mar2023Localised

Description: 2 PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 20
Url: /Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v4.1-15Mar2023Localised.docx

Papers CoG 16.07.2025

Description: Date Time Location Chair Agenda Council of Governors 16/07/2025 14:00 - 15:30 Conference Room, Heartbeat/Microsoft Teams Jenni
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-16.07.2025.pdf

51 to 60 of 66

Previous … 3 4 5 6 7 Next